Form 4: Voyager CEO Sells Shares for Tax Obligations

Voyager Therapeutics' President and CEO, Alfred Sandrock, sold 12,192 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Alfred Sandrock, President and CEO of Voyager Therapeutics, Inc., sold 12,192 shares of common stock.
• The sale occurred on February 10, 2026, at a weighted average price of $3.78 per share, with individual transactions ranging from $3.68 to $3.91.
• The transaction was not a discretionary trade but a 'sell-to-cover' to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 9, 2026.
• Following the transaction, Mr. Sandrock beneficially owns 509,989 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is non-discretionary and solely for tax purposes, not reflecting a change in management's outlook or a strategic divestment.

Positives

• The sale was non-discretionary, indicating it was not a market-timing decision by the insider.
• The transaction is a routine event related to compensation and tax obligations, not a reflection of a change in company fundamentals.

Negatives

• A reduction in direct insider ownership, although for a non-discretionary reason.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions are common in the biotechnology and pharmaceutical industries, where executive compensation often includes restricted stock units. These sales are typically viewed as administrative rather than indicative of management's sentiment about the company's future prospects, distinguishing them from discretionary open-market sales.

Comparison to Industry Standards

• Sell-to-cover transactions are standard practice across industries for executives receiving equity compensation.
• Similar non-discretionary sales are frequently observed at companies like Biogen (BIIB) or Sarepta Therapeutics (SRPT) when restricted stock units vest, reflecting a common mechanism for managing tax liabilities associated with equity awards.

Related Party Transactions

• The sale of shares by Alfred Sandrock, an officer and director, to cover tax obligations related to his equity compensation is a routine related party transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a non-discretionary tax-related sale, not indicative of a change in company fundamentals or management confidence.
• Employees: No direct impact.

Key Dates

Recommendation

The transaction is a routine, non-discretionary 'sell-to-cover' to satisfy tax obligations related to restricted stock unit vesting. It does not signal a change in the company's fundamentals or management's confidence, thus it should not influence an investment decision to buy or sell based solely on this filing. A 'hold' recommendation is appropriate as this event is neutral.

Keywords

Voyager Therapeutics, VYGR, Alfred Sandrock, Insider Transaction, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Biotechnology, Pharmaceuticals